PB-28

Category	SARS-CoV
CAS	172906-90-0
Description	PB28 is a cyclohexylpiperazine derivative and a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 is also a σ1 antagonist with a Ki of 0.38 nM. PB28 is less affinity for other receptors. PB28 inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 can modulate SARS-CoV-2-human protein-protein interaction. PB28 induces Caspase-independent Apoptosis and has antitumor activity.

Quotation Now

Product Information

Synonyms	PB-28\|PB28\|172906-90-0\|1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine\|CHEMBL53325\|1-Cyclohexyl-4-(3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl)piperazine\|1-cyclohexyl-4-(3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)piperazine\|1-cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine\|SCHEMBL466974\|UNII-XTX7Z22467\|GTPL6681\|CHEBI:189648\|XTX7Z22467\|BDBM50048866\|HY-108511A\|NCGC00165875-01\|NCGC00165875-02\|NCGC00165875-03\|CS-0077889\|Q7118323\|1-(3-(5-methoxytetralin-1-yl)propyl)-4-cyclohexylpiperazine\|1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-piperazine\|1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)propyl]piperazine\|1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-n-propyl]piperazine\|Piperazine, 1-cyclohexyl-4-(3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl)-
IUPAC Name	1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine
Molecular Weight	370.6
Molecular Formula	C24H38N2O
Canonical SMILES	COC1=CC=CC2=C1CCCC2CCCN3CCN(CC3)C4CCCCC4
InChI	InChI=1S/C24H38N2O/c1-27-24-14-6-12-22-20(8-5-13-23(22)24)9-7-15-25-16-18-26(19-17-25)21-10-3-2-4-11-21/h6,12,14,20-21H,2-5,7-11,13,15-19H2,1H3
InChIKey	PHRCDWVPTULQMT-UHFFFAOYSA-N
Purity	>99 %
Solubility	H2O: ~10 mg/mL at 60 °C
Appearance	White solid
Storage	desiccated
Complexity	428
Exact Mass	370.298413840
In Vitro	PB28 (15-25 nM; 24-48 hours; MCF7 and MCF7 ADR cells) treatment shows an accumulation in the G0-G1 phase for MCF7 and MCF7 ADR cells that are time and concentration independent. PB28 has a higher σ2 receptor affinity expressed as Ki (0.28 nM and 0.17 nM in MCF7 and MCF7 ADR cells, respectively) than σ1 receptor affinity (13.0 nMand 10.0 nM, respectively)[. PB28 inhibits cell growth of MCF7 and MCF7 ADR cells with IC50s of 25 nM and 15 nM, respectively after 2-day treatment. PB28 induces Apoptosis through a Caspase-independent pathway. PB28 also reduces P-gp expression in a concentration- and time-dependent manner (approximately 60% in MCF7 and 90% in MCF7 ADR). PB28 displays antiproliferative and cytotoxic effects in both C6 rat glioma and SK-N-SH human neuroblastoma cell line.
In Vivo	PB28 (10.7 mg/mL; intraperitoneal injection; daily; for two weeks; C57BL/6 female mice) treatment inhibits tumor growth in Panc02 tumor burden mice. PB28 also conferres a survival advantage for mice.
Target	Ki: 0.68 nM (σ2 receptor); 0.38 nM (σ1 receptor)
XLogP3-AA	5.4